Clarifications on new biosketch format issued

Since establishing changes to biosketch format requirements over a year ago, the NIH has received questions and feedback from the biomedical research community on how to best implement these changes. In response, clarifications on instructions and format pages were issued on Mar. 23 for applications due on or after May 25, 2016, as follows:

  • A URL for a publication list is optional, and, if provided, must be to a government website (.gov) like My Bibliography.
  • Publications (peer-reviewed and non-peer-reviewed) and research products may be cited in both the personal statement and the contributions to science sections.
  • Graphics, figures, and tables are not allowed.
  • The requirement that the past three years of research support are listed in order of relevance has been removed.
  • There is an option to add other names used to author research products in section A.
  • Research products can include conference proceedings such as meeting abstracts, posters, or other presentations.
  • Research products that are under development, such as manuscripts that have not yet been accepted for publication, can be mentioned in the narrative sections. However, they cannot be included as one of their citations.

The FORMS-D (replacing FORMS-C) application instructions were posted on Mar. 25 and have a single set of biosketch instructions and a link to the new format page. The NIH Forms page can also be used as reference. Researchers are encouraged to use the Science Experts Network Curriculum Vitae (SciENcv) as a tool to build their biosketches. A YouTube video and FAQs are available to assist.

TTBD Startup Spotlight: ReelDx, Inc.

reel-dx-dark-blueReelDx, Inc. is an OHSU startup company developing secure, HIPAA-compliant medical video platforms for educational and clinical use. Launched in 2013, the company’s initial goal was to improve medical instruction by creating ReelDx Education, a video library of case studies to broaden medical student’s experiences in real-world health care settings. The company has since expanded to incorporate an additional video platform, called medvid.io. This video platform is aimed at improving the patient and physician relationship through asynchronous video telemedicine, video check-in visits, and recordings of discharge instructions for patient use.

Today, ReelDx Education maintains a vibrant and growing library of over 600 video case studies, describing over 1,000 topics. Participating medical and nursing schools, physician assistant programs, and other educational systems are incorporating these video into their curriculum to support students in the medical field. The main goal of this initiative is to provide a full and comprehensive educational platform that allows medical students the opportunity to experience and learn from a variety of clinical cases. Videos uploaded into the ReelDx Education library are filmed by teachers and trainers at participating academic medical centers, private practices, ambulatory agencies, and hospitals. Since its inception, ReelDx Education has been rapidly expanding its library, adding to their neurology, pediatrics, pre-emergency room, and eating disorder cases, to name a few. The ReelDx Education model hopes to improve upon traditional in-person medical rounds by offering supplementary case study videos in the classroom to cover situations students may need further reinforcement or exposure to during their medical training.

The ReelDX medvid.io platform aims to improve patient and physician communication by offering safe and convenient alternatives to record and review discharge instructions, patient education, and between visit check-ins. After medical appointments, many patients struggle to retain the instructions provided to them by their physician. According to the National Center for Biotechnology Information, patients can immediately forget 40 percent to 80 percent of the information received during their medical visit. This can be problematic for many patients, along with their family or care network, since many rely on the information given to them in order to take proactive or preventative measures for their medical condition. The medvid.io platform directly addresses this issue and offers an effective solution to help patients adhere to their medical instructions.

While medvid.io assists patients in a variety of situations, it can also prove to be a beneficial tool for physicians. The ability to quickly check in with your patient, ask follow up questions, and conduct video telemedicine appointments to quickly address any issues or ambiguity can enable physicians to continue care efficiently and effectively without necessitating a return trip to the doctor’s office.

A common question that arises about the ReelDx business model is how they manage to keep their videos secure and HIPAA compliant. When asked about the security measures of the patient videos, ReelDx CEO, Bill Kelly, stated, “We’ve built a platform from the ground-up to be HIPAA compliant. We are in the cloud, but we use encryption in storage and in transit. We also use a very rigorous, user-based security system to ensure that only authorized users can see the videos.”

Looking forward, the ReelDx team is currently researching ways to apply additional analytic features to the medvid.io platform. This includes the ability to transcribe the audio portion of the video and embed the transcript as a note in the medical record, or as searchable text in a larger library. Among other additions, ReelDx is also working with partners to add ways to automate the measurement of patient emotional responses through facial and nonverbal cues, allowing behavioral and mental health practitioners using their technological platform to get a sense of their patient’s current emotional health. With thousands of videos currently being finalized in the company’s queue, and tens to hundreds of thousands expected to be added over the next several months, Mr. Kelly expects the medvid.io platform to grow rapidly as ReelDx is poised to meet the growing demand in the telemedicine market. When asked if he had any entrepreneurial advice to give to potential company leaders, he stated, “Make sure you listen to the market and don’t listen to the skeptics.”

 

School of Dentistry Research Day, Mar. 31

Join the School of Dentistry this Thursday for its annual Research Day, highlighting the research activities and achievements made by faculty, staff, and students within the school. Research is an integral component of the school’s mission, significantly contributing to the education and clinical training of students.

Download the SoD Research Day agenda

View the SoD Research Day agenda

Thursday, Mar. 31
12 to 4 p.m.
Collaborative Life Sciences Building

Luisa A. DiPietro, D.D.S., Ph.D., professor and director of the Center for Wound Healing and Tissue Regeneration at the University of Illinois, Chicago, who will present the keynote lecture, “Wound healing – Inside and out,” at 12:30 p.m. DiPietro’s laboratory studies how wounds heal, with the ultimate goal of developing therapies that will allow humans to regenerate perfect tissue after an injury.

The day will also include welcome messages from the School of Dentistry’s associate dean for research David B. Morton, Ph.D., Student Research Fellowship Awards, and poster presentations.

 

OHSU’s Entrepreneur-in-Residence Q&A: Richard Rylander

OHSU’s entrepreneur-in-residence program was established in September 2015 to help identify technologies with commercial promise and provide OHSU researchers with advice and real-world insights about the commercialization process. The entrepreneurs in residence also provide their business world expertise and experience to OHSU’s existing startup companies and work closely with Technology Transfer and Business Development in their broader commercialization efforts.

Richard RylanderOHSU entrepreneur-in-residence Richard Rylander, Jr., M.B.A.,  helps to accomplish these goals by developing and improving upon OHSU startup company operations. His specific roles include assisting in product pricing, market analysis, business plan guidance, strategic planning, and financing, just to name a few.

We sat down to talk with Rylander to get his thoughts on startup companies.

What is your entrepreneurial background and experience managing startup companies?

I have more than 40 years of experience in the pharmaceutical and biotech industry, with roles ranging from sales, marketing, training, market research, and executive management. Over the span of my career, I have been involved in the launch of approximately 18 product development projects and have provided consulting services for a number of startup companies, in a wide range of development stages. I’ve also helped start several companies, taking on various executive roles to help move the company forward in commercializing their products.

What brought you to OHSU?

I have been involved in the startup and technology commercialization space for decades. I am currently living right across the bridge in Battleground, Washington, so I was curious about opportunities to help grow Pharma/Biotech in the Portland area. Ultimately, my goal is to help the community and to make a difference in the biomedical industry. I would also like to see an increase in the life science startups in the Portland area, and build upon OHSU’s life science ecosystem.

What can you bring to the OHSU community and what would you like to see changed during your time here?

Ultimately, I would like to see all OHSU startup companies succeed. To do that, entrepreneurs-in-residence can assist OHSU startup company executives deal with a wide range of challenges, including product pricing, marketing, market analysis, human resources, and investment pitch preparation. Last year, OHSU launched six startup companies, and we are working to increase that number in the future. We hope to assist these companies to create successful business strategies and help them flourish and to develop an attractive business plan to entice acquisition from a larger company (if that is their plan).

What do you enjoy doing in your spare time?

I have been happily married for about 45 years and spend a lot of time with my family. I also enjoy building and repairing computers, reading, gardening, and bowling.

For more information on the Entrepreneur-in-Residence program or to inquire about startup companies at OHSU, please contact Daphne Emerson at emersond@ohsu.edu.

 

Who’s presenting at Research Week 2016? Announcing this year’s keynotes

Another Research Week is on the horizon, and with it comes another round of engaging keynote speakers!

Laurie A. Boyer, Ph.D.

Laurie A. Boyer, Ph.D.

Starting off the week will be student’s choice keynote presenter Laurie A. Boyer, Ph.D., Irvin and Helen Sizer Career Development Associate Professor of Biology at MIT. Her talk, “Mending a broken heart,” will focus on recent efforts to dissect the transcriptional and epigenetic mechanisms that control cell fate decisions during mammalian heart development and how faulty regulation of these programs can lead to congenital heart defects. She will also discuss how she have begun to exploit the principles learned from her developmental studies to promote cardiac regeneration. Boyer earned her doctorate in biochemistry from the University of Massachusetts Medical School, and has received numerous awards including a Pew Scholar in the Biomedical Sciences, the Smith Family Foundation for Excellence in Biomedical Research, and Massachusetts Life Sciences Center.
Monday, May 2, 12 to 1 p.m., OHSU Auditorium

David J. Paterson, M.A., M.Sc., D.Phil., D.Sc.

David J. Paterson, M.A., M.Sc., D.Phil., D.Sc.

David J. Paterson, M.A., M.Sc., D.Phil., D.Sc., professor of cardiovascular physiology, joint director of the Burdon Sanderson Cardiac Science Center, and vice dean of the Division of Medical Sciences at Oxford University, will be presenting the annual Brookhart Lecture later in the week. His talk, “Neurocardiology: Therapeutic opportunity?” will focus on the relationship between cellular and molecular mechanisms in cardio-respiratory control during physiological stress, and how neural dysregulation contributes to cardiac pathology. Paterson was born and educated in New Zealand, and is a graduate of the Universities of Otago, Western Australia, and Oxford. He is a leading cardiorespiratory physiologist and a world authority in cardiac-neural control.
Thursday, May 5, 4 to 5 p.m., Richard Jones Hall, room 4340

Stay tuned for more events as the agenda for Research Week 2016 is finalized.

Hessell and ONPRC team discovers antibody treatment that halts SHIV infection in infant macaques

This post has been updated with proper author attribution.

OHSU researchers at the Oregon National Primate Research Center have shown that early short-term treatment with human anti-HIV1-1 monoclonal antibodies halts simian HIV infection, a chimeric virus that shares key properties with HIV,  in infant macaques. The study, published March 21 in Nature Medicine, shows that antibodies given to a baby macaque within 24 hours after being exposed to simian HIV can clear the virus completely, a discovery that paves the way for future therapies to prevent mother to child transmission of HIV.

(Left to Right) Don Siess, Michael Axthelm, Ann Hessell, Christoph Kahl, Alfred Legasse, Jeffrey Stanton, Byung Park, David Burke

(Left to Right) Don Siess, Michael Axthelm, Ann Hessell, Christoph Kahl, Alfred Legasse, Jeffrey Stanton, Byung Park, David Burke

Transmission of HIV from mother to child remains the most common way for children to become infected. Current therapeutic standards include treating HIV-positive pregnant women with antiretroviral therapy during pregnancy and birth while babies born to these women receive HIV medicine for 6 weeks after birth. These therapies carry health risks of their own and there are many women throughout the world who lack access to them.

In this study, Ann Hessell, Ph.D., Nancy Haigwood, Ph.D., and colleagues administered anti-HIV-1 human neutralizing monoclonal antibodies (NmAbs) subcutaneously on days 1, 4, 7 and 10 after the baby macaques were exposed to SHIV orally. The team quantified the systemic distribution of NmAb in multiple tissues within 24 hours following administration. Replicating virus was found in these tissues by day 1 in animals that did not receive antibody treatment while those treated with NmAb remained free of virus in both blood and tissue at 6-months after exposure.

Read the full media release.

The study was funded by U.S. Public Health Service grants from the National Institutes of Health and the Eunice Kennedy Shriver National Institute of Child Health and Human Development: R01-HD080459 (N.L.H) and P51-OD011092 (J. Robertson), P51-OD011092 pilot funding, (E.E.); the Elizabeth Glaser Pediatric AIDS Foundation (N.L.H.); and The Foundation for AIDS Research (amfAR) 108823-55-RGRL (N.L.H.).

This work also was funded, in part, by the intramural research program of the Vaccine Research Center, and of the Laboratory of Molecular Microbiology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Division of Health & Human Services, U.S. Public Health Service.

 

 

NIH seeks public comment on draft clinical trial protocol template

In an effort to make it easier for investigators to prepare protocols that are consistently organized and contain all the information necessary for the clinical trial to be properly reviewed, the NIH and FDA are developing a template with instructional and sample text for NIH-funded investigators to use in writing protocols for phase 2 or 3 clinical trials that require applications for Investigational New Drugs (INDs) or Investigational Device Exemptions (IDEs). They would like you to weigh in on the template.

Comments on the draft template from investigators, investigator-sponsors, and institutional review board members, and any other stakeholders who are involved in protocol development and review can be submitted here through April 17, 2016. Perspectives on the utility of such a template and whether the instructional and sample text is clear and readable are of particular interest.

Get ready for Research Week with these pre-event workshops

All OHSU researchers (especially students and trainees, but really everyone!) are invited to attend these skill-building seminars to help you prepare for giving an oral or poster presentation at OHSU Research Week, May 2-6, 2016.

How to make and present a poster
Friday, Apr. 1
12 to 1 p.m.
MRB 310

You’ve done the research, now you need to pull it together for you Research Week poster! This seminar will present key tips for creating and presenting a poster that will be memorable for all the right reasons. Presented by Jackie Wirz, Ph.D., assistant professor, OHSU Library.
 
Prepare for the Three-Minute Thesis
Friday, Apr. 8
12 to 1 p.m.
BRB 381

Can you effectively present your thesis in three minutes? This workshop, presented by Jackie Wirz, Ph.D., and past 3MT winners Kate Leobold, Asia Mitchell, and Que Chen, is recommended for both Research Week oral presenters as well as Three-Minute Thesis competition participants.
 
How to give a scientific talk
Friday, Apr. 22
12 to 1 p.m.
BRB 381
This workshop, presented by Kimberly Beatty, Ph.D., is recommended for both Research Week oral and poster presenters.
 
How to network
Friday, Apr. 29
12 to 1 p.m.
MRB 310
Make the most of this year’s networking night! This workshop, presented by Mike Matrone, Ph.D., is recommended for students and postdocs.

Questions or concerns about any of these workshops? Contact the planning committee.

The three laws of communication: Jean-Luc Doumont lecture, Apr. 7

Useful as each of them can be, a large body of tips and tricks is impossible to remember, at least in a practical, usable way, unless it is structured into a balanced, meaningful hierarchy. In this talk, Jean-luc Doumont, Ph.D., proposes and illustrates three simple yet solid ideas that lead to more effective communication and that underpin every otherJean Luc Doumont guideline: easy to remember, readily applicable, and always relevant—in short, valuable for the rest of your life.

Thursday, Apr. 7
3:30 to 5:30 p.m.
Collaborative Life Sciences Building
Tiered lecture hall, 3A003A/B

An engineer and Ph.D. in applied physics, Jean-luc Doumont is acclaimed worldwide for his no-nonsense approach, his highly applicable, often life-changing recommendations on a wide range of topics, and Trees, maps, and theorems, his book about “effective communication for rational minds.”

OCTRI Biomedical Innovation Program, funding for drug discovery

The Oregon Clinical and Translational Research Institute (OCTRI) and the Office of Technology Transfer & Business Development (TTBD) are pleased to announce a new funding opportunity to support drug discovery and therapeutic technology development efforts at OHSU.

The Biomedical Innovation Program (BIP) Drug Discovery/Therapeutic Track is a funding mechanism that aims to accelerate creative, trans-disciplinary drug discovery, and therapeutic development research. Examples of responsive projects may include (but are not limited to) research involving target validation, development of small molecules, antibodies, vaccines and biologics.

The current RFA can be found here.
Letters of intent are due on April 14, 2016.

Program highlights:

  • Up to $60,000 in funding
  • Project management and hands-on support from BIP staff
  • Access to project-specific mentors and experts

Questions? Please contact Jonathan Jubera at jubera@ohsu.edu, or visit the OCTRI Funding Opportunities page for more information.

Welcome to the Research News Blog

Welcome to the Research News Blog

OHSU Research News is your portal to information about all things research at Oregon Health & Science University. Visit often for updates on events, discoveries, and important funding information.

Participation Guidelines

Remember: information you share here is public; it isn't medical advice. Need advice or treatment? Contact your healthcare provider directly. Read our Terms of Use and this disclaimer for details.

Categories

Archives